Comparing 22 and 19G needles with EUS-FNB sampling for Cancer Gene Panel Test

A prospective randomized controlled trial of comparing 22 and 19G needles for tissue sampling with EUS-FNB for Cancer Gene Panel Test in solid pancreatic masses

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1062210071

Enrollment

Registered

2022-01-19

Start date

2022-02-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic mass

Interventions

RCT study (1:1 ratio) 1 First EUS-FNB using 22G needle, second EUS-FNB using 19G needle 2 First EUS-FNB using 19G needle, second EUS-FNB using 22G needle

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with solid pancreatic mass planned for Cancer Gene Panel Testing using EUS-FNB samples

Exclusion criteria

Exclusion criteria: Performance status 3-4 Bleeding tendency or platelet count less than 50000/mm2 Taking two or more anti-thrombotic drugs Difficult to perform EUS-FNB with safe due to interval vessels Pregnant Patients who could not obtain suitable informed consent Patients judged by the reseach doctors as inappropriate subjects

Design outcomes

Primary

Measure	Time frame
Collection rate of adequate tissue sampling for Cancer Gene Panel Test	—

Secondary

Measure	Time frame
Tumor cell ratio Tissue section surface area Estimated amount of nucleic acid Core tissue length Histology score Technical success Adverse event Success rate of Cancer Gene Panel Test When there was a poorly enhanced area in tumor with CE-EUS, the above pathological evaluation will be performed using tissue samples obtained from poorly enhanced area	—

Contacts

Public ContactMatsumoto Kazuyuki

Okayama University Hospital

matsumoto.k@okayama-u.ac.jp+81-86-235-7219

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026